arachidonoyl serinol

Arachidonoyl serinol is a synthetic small molecule analog of the endocannabinoid anandamide (arachidonoylethanolamide) investigated for its potential antineoplastic properties. It was designed to overcome the therapeutic limitations of anandamide, which is rapidly hydrolyzed by the enzyme fatty acid amide hydrolase (FAAH). By substituting the ethanolamine head group of anandamide with a serinol group, the molecule gains steric bulk and additional alcohol functional groups, making it resistant to FAAH-mediated degradation. This modification is intended to prolong the molecule's half-life, allowing it to be metabolized by cyclooxygenase-2 (COX-2) into cytotoxic J-series prostamides, such as 15d-PMJ2, within COX-2-overexpressing cancer cells. Despite this design, preclinical studies in tumorigenic keratinocytes have shown that arachidonoyl serinol lacks significant cytotoxic efficacy compared to other anandamide derivatives like Arvanil or m-methanandamide.

Other names

N-arachidonoyl serinolarachidonyl serinolN-arachidonoylserinol